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A B S T R A C T
Purpose
Outcome of childhood acute lymphoblastic leukemia (ALL) improved greatly by intensifying che-
motherapy for all patients. Minimal residual disease (MRD) levels during the ﬁrst months predict
outcome and may select patients for therapy reduction or intensiﬁcation.
Methods
Patients 1 to 18 years old with ALL were stratiﬁed on the basis of MRD levels after the ﬁrst and
second course of chemotherapy. Thereafter, therapy was substantially reduced in patients with
undetectable MRD (standard risk) and intensiﬁed in patients with intermediate (medium risk) and
high (high risk) levels ofMRD. Seven hundred seventy-eight consecutive patientswere enrolled. The
method of analysis was intention-to-treat. Outcome was compared with historical controls.
Results
InMRD-based standard-risk patients, the 5-year event-free survival (EFS) rate was 93% (SE 2%), the
5-year survival rate was 99% (SE 1%), and the 5-year cumulative incidence of relapse rate was 6%
(SE 2%). The safety upper limit of number of observation years was reached and therapy reduction
was declared safe.
MRD-based medium-risk patients had a signiﬁcantly higher 5-year EFS rate (88%, SE 2%) with
therapy intensiﬁcation (including 30 weeks of asparaginase exposure and dexamethasone/
vincristine pulses) compared with historical controls (76%, SE 6%). Intensive chemotherapy and
stem cell transplantation inMRD-based high-risk patients resulted in a signiﬁcantly better 5-year EFS
rate (78%, SE 8% v 16%, SE 8% in controls). Overall outcome improved signiﬁcantly (5-year EFS
rate 87%, 5-year survival rate 92%, and 5-year cumulative incidence of relapse rate 8%) compared
with preceding Dutch Childhood Oncology Group protocols.
Conclusion
Chemotherapy was substantially reduced safely in one-quarter of children with ALL who were
selected on the basis of undetectable MRD levels, without jeopardizing the survival rate. Outcomes
of patients with intermediate and high levels of MRD improved with therapy intensiﬁcation.
J Clin Oncol 34:2591-2601. © 2016 by American Society of Clinical Oncology
INTRODUCTION
In the last ﬁve decades, survival rates for children
with acute lymphoblastic leukemia (ALL) have
improved by intensifying chemotherapy for all
patients.1 By the 1970s, one-third of patients were
being cured with moderately intensive thera-
pies, implying that treatment could be reduced
for some patients. Assessment of early therapy
response by measuring minimal residual disease
(MRD) is the strongest predictor of survival,2-6
ﬁrst shown in the late 1990s by different groups,
including a study by Associazione Italiana Ema-
tologia ed Oncologia Pediatrica (AIEOP)–Berlin-
Frankfurt-Mu¨nster (BFM) and Dutch Childhood
Oncology Group (DCOG).4 Their BFM-based pro-
tocols, including the DCOG ALL8-study,7 identiﬁed
three risk groups by MRD levels after courses IA and
IB: standard risk (SR), medium risk (MR), and high
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risk (HR), with 5-year event-free survival (EFS) rates of 98% (SE 2%),
76% (SE 6%), and 16% (SE 8%), respectively.2,8 The DCOG ALL10
protocol, which aimed to improve overall outcome, reduced therapy in
patients with the lowestMRD levels without jeopardizing outcome, and
improved outcome in patients with intermediate and high MRD levels
by intensifying therapy, is presented here.
METHODS
Patients
Between November 2004 and April 2012, 778 consecutive children
(1 to 18 years old) with newly diagnosed ALL were treated with the ALL10
Not eligible for ALL10
(n = 84)
Mature B-ALL
(n = 0)
Pre-existing clinical 
contra-indications
(n = 7)
Treated with systemic
corticosteroids and/ 
or cytostatic drugs in 4
weeks prior to diagnosis
(n = 7)
Presence of BCR-ABL 
fusion transcript (treated 
according to
EsPhALL protocol)
(n = 17)
Age < 1 year (treated 
according to
Interfant protocol)
(n = 28)
Absence of informed 
consent
(n = 6)
Settlement in the 
Netherlands < 3 months
(n = 14)
Not treated in a
Childhood Oncology 
Centre
(n = 5)
Treated according to the
succeeding ALL11
protocol
(n = 2)
Death before start
of treatment
(n = 1)
No intention-to-treat
according to ALL10
(n = 3)
Standard Risk (SR)
(n = 194; 24.9%)
Medium Risk (MR)
(n = 490; 63.2%)
High Risk (HR)
(n = 81; 10.4%)
Death before 
stratification
(n = 13; 1.7%)
Intention-to-treat
according to ALL10
(n = 778)
Total number of 
Childhood ALL patients 
in the Netherlands
(N = 865)
Fig 1. Overview of patients with acute lym-
phoblastic leukemia (ALL) in the Netherlands and
treatment according to ALL10.
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protocol (Fig 1). Infants younger than 1 year (Interfant protocol)9 and
BCR-ABL–positive ALL cases (EsPhALL protocol) were excluded.10 The
protocol was approved by institutional review boards. Informed consent
was signed by parents and patients according to Dutch law.
Therapy
Initial therapy with courses IA, IB, and M, and MRD-based strati-
ﬁcation, were identical to the historical DCOG ALL8 control group.2,7,8
MRD levels were measured after IA (time point [TP] 1) and IB (TP2).
Subsequent intensiﬁcation therapy in ALL10 was substantially reduced in
patients with SR, intensiﬁed in patients with MR, and strongly intensiﬁed
in patients with HR (Appendix Fig 1, online only).
SR. Protocol IV was substantially reduced by deleting 14 days
6-thioguanine 60 mg/m2/day, one dose cyclophosphamide 1,000 mg/m2,
8 days cytarabine 75 mg/m2/dose, two intrathecal doses methotrexate
(MTX), and four doses doxorubicin (30 mg/m2/dose). Vincristine (VCR)
(1.5 mg/m2/dose) was reduced from four to two doses and dexamethasone
(10 mg/m2/day) from 3 to 2 weeks. This resulted in a mild intensiﬁcation
course IV, with only 2 weeks dexamethasone, two doses VCR, and one
dose PEG-asparaginase. This is a considerable decrease in intensity
compared with, for instance, the contemporary intensiﬁcation course
of AIEOP-BFM 2000, which uses the same stratiﬁcation4 (Appendix
Table A1, online only). Maintenance therapy consisted of only oral
mercaptopurine/MTX.
MR. MR intensiﬁcation and maintenance were based on the Dana-
Farber Cancer Institute protocol,11 including intensive PEG-asparaginase
(15 doses) and dexamethasone/VCR pulses during maintenance.
HR. HR patients received six HR courses (HR1-HR6) according to
the Australian and New Zealand Children’s Haematology/Oncology
Group protocol,12 followed by course II and maintenance or three
HR courses plus allogeneic stem cell transplantation (alloSCT; Appendix
Fig A1, online only).
CNS-directed therapy. SR and MR patients received a total of nine
and 14 intrathecal triple-therapy administrations, respectively. HR patients
received nine to 12 and, if not transplanted, 12 to 15 intrathecal therapies.
Patients with CNS2 (nontraumatic puncture, # 5 WBC/mL CSF with
identiﬁable leukemic cells), CNS3 (nontraumatic puncture, . 5 WBC/mL
CSF with identiﬁable leukemic cells), or TLP+ (traumatic lumbar puncture
with leukemic cells) received two additional intrathecal therapies in
protocol I, and HR patients received another two intrathecal therapies in
protocol II. HR patients older than 3 years who were not receiving stem cell
transplantation (SCT) received 12-Gy cranial irradiation.
MRD Stratification
Polymerase chain reaction (PCR)–detected MRD was evaluated
according to EuroMRD guidelines.13,14
Patients were stratiﬁed to SR if they met all of the following criteria:
• cytomorphologic complete remission (CR) day 33
• MRD-negativity at TP1 and TP2 (at least one MRD-PCR target with
a quantitative range of 1024 and one MRD-PCR target with
a quantitative range of 5 3 1024 and sensitivity of 1024)
• no MLL-AF4 rearrangement
• no prednisone-poor response
• no CNS/testicular involvement (CNS status; Table 1)
Patients were stratiﬁed to HR if they met at least one of the following
criteria:
• TP1 MRD level of $ 5 3 1024 or unknown and TP2 MRD level of
$ 5 3 1024
• MLL-AF4 rearrangements
• poor prednisone response
• no CR day 33
All others and patients with inconclusive/missing MRD data were
stratiﬁed to MR. Children with Down syndrome (DS) were not eligible for
HR therapy.
Statistical Analysis
Because therapy was reduced in SR, a noninferiority design was used
to ensure noworse outcome compared with historical controls. InMR/HR,
we intensiﬁed therapy and superiority questions were asked.
In SR, there was a 20% probability that ALL10 is incorrectly declared
unsafe at a safe event rate of 2% per year and a 5% probability that ALL10 is
incorrectly declared safe at an unsafe event rate of 3% per year. For every
second event, the cumulative observation time (T) of all SR patients is
compared with the predeﬁned upper and lower safety limits, based on the
sequential probability ratio test for exponential distribution (Appendix
Table A2, online only).15
Events were induction failure (deﬁned as event at day 0), relapse,
death, or secondary malignancy. Analyses were by intention-to-treat. EFS
was computed from diagnosis to ﬁrst event or last follow-up; overall
survival (OS) was computed from diagnosis to death or last follow-up. The
Kaplan-Meier methodology was used to estimate EFS/OS, Cox models to
assess effects of covariates on EFS/OS, and the local test to compare EFS
between ALL10 and controls.
The cumulative incidence of relapse (CIR) from diagnosis to relapse
was estimated by a competing-risk model.16 CIR curves were compared by
Gray’s log-rank test.17 Regression on CIR function was performed by Fine
and Gray’s model.18 Landmark analysis was performed at day 79 (MRD
TP2), including only patients who survived up to day 79. The median
follow-up time was assessed using the reverse Kaplan-Meier method.19
Statistical analyses were performed in SPSS-Rel. 20.0.2012 (SPSS, Chicago,
IL) and competing-risks models by the mstate library in R-15.20-22
RESULTS
Patient Characteristics
Table 1 presents an overview of patient characteristics,
outcome data, and the univariate survival analysis. ALL10 en-
rolled more adolescents 15 to 18 years of age (7.3%) than pre-
vious protocols (1.4%, 4.1%, and 3.6% on ALL7, ALL8, and
ALL9, respectively) as a result of better outcomes of adolescents
on pediatric versus adult ALL protocols.23 For unknown reasons,
the number of patients with DS (5.1%) was higher when com-
pared with 1.8%, 1.9%, and 2.8% in ALL7, ALL8, and ALL9,
respectively.
Stratification
In 92 of 778 cases (11.8%), MRD classiﬁcationwas not feasible
because of a lack of material and early events (6.9%) or an absence
of (sensitive) MRD targets (4.9%). Among 686 MRD-stratiﬁed
cases, 198 were SR, 460 MR, and 28 HR (Fig 2). Including all 778
patients and all stratiﬁcation criteria, the ﬁnal stratiﬁcation was 194
SR (24.9%), 490 MR (63.0%), 81 HR (10.4%), and 13 deaths
(1.7%) that occurred before stratiﬁcation.
Outcomes
Table 2 presents an overview of events and 5-year outcome
data in ALL10. The median follow-up was 80 months (range 36 to
125 months). Thirteen patients (1.7%, including seven with DS)
died during induction, two (0.3%) did not achieve CR after HR1,
and 763 (98.0%) achieved CR. Induction deaths were as a result of
infection in eight patients, intracerebral bleeding/infarction in two,
multiorgan failure in one, and unknown causes in two. Twenty
patients (2.6%) died during CR: 13 as a result of infection (in-
cluding four patients with DS), one pancreatitis, two sudden death,
www.jco.org © 2016 by American Society of Clinical Oncology 2593
Acute Lymphoblastic Leukemia Therapy Reduction and Intensiﬁcation
Downloaded from ascopubs.org by Leids Univers Medisch Centrum on February 10, 2017 from 132.229.211.122
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
and four SCTrelated. Five patients (0.6%) had a second malignancy
(acute myeloid leukemia, osteosarcoma, leptomeningeal gliomatosis,
melanoma, and histiocytic sarcoma); 69 patients (8.9%) relapsed.
The 5-year EFS and OS rates were 87.0% (SE 1.2%) and
91.9% (SE 1.0%), respectively. The 5-year CIR of all relapses was
8.3% (SE 1.0%), of which isolated CNS relapse was 1.4% (SE
0.4%).
Figure 3 displays overall EFS, OS, and CIR for ALL10 intention-
to-treat patients.
Down Syndrome (DS)
Appendix Table A3 (online only) presents outcome data of
DS versus non–DS patients. Because seven of 40 patients with DS
(18%) died during induction, only 33 were stratiﬁed: 7 SR and
26MR (among whom twoMRD-HRwere assigned toMR according
to protocol). Four of 40 patients died during remission (10%), four
relapsed (10%), and 25 are in CCR (63%). The 5-year EFS and OS
rates for DS-ALL cases were 66.1% (SE 7.8%) and 65.2% (SE 8.0%),
respectively, versus 88.1% (SE 1.2%) and 93.3% (SE 0.9%) for
non–DS-ALL cases. The protocol was amended for DS by deleting
anthracyclines during induction. Numbers were too low to analyze
the effect.
Outcomes by Patient Characteristics
Table 1 and Appendix Tables A4 and A5 (online only) pres-
ent outcomes by patient characteristics. Outcomes were not
Table 1. Overview of Patient Characteristics, Outcome Data, and Univariate Survival Analysis
Variable
No. of
Patients
EFS OS CIR
5-Year,
% (SE)
Estimated Hazard
Ratio (Univariate
Cox CI) P
5-year,
% (SE)
Estimated Hazard
Ratio (Univariate
Cox CI) P
5-Year,
% (SE)
Estimated Hazard
Ratio (Univariate
Fine and Gray CI) P
Sex
Male 420 85.3 (1.7) 1.00 (Ref) 91.0 (1.4) 1.00 (Ref) 9.6 (1.5) 1.00 (Ref)
Female 358 89.2 (1.7) 0.76 (0.52 to 1.12) .16 92.8 (1.4) 0.84 (0.52 to 1.34) .46 6.7 (1.4) 0.74 (0.46 to 1.19) .22
Age, years
1-4 361 91.5 (1.5) 1.00 (Ref) 94.7 (1.2) 1.00 (Ref) 4.2 (1.1) 1.00 (Ref)
5-9 230 86.1 (2.3) 1.77 (1.10 to 2.85) .018 91.8 (1.9) 1.54 (0.84 to 2.83) .16 10.9 (2.1) 2.90 (1.58 to 5.31) , .001
10-14 130 80.1 (3.6) 2.73 (1.65 to 4.51) , .001 88.4 (2.8) 2.49 (1.32 to 4.66) .005 13.4 (3.1) 3.44 (1.76 to 6.73) , .001
15-18 57 78.9 (5.4) 2.71 (1.39 to 5.26) .003 82.2 (5.1) 3.28 (1.55 to 6.97) .002 12.7 (4.5) 3.21 (1.31 to 7.88) .011
WBC count
, 25 554 87.1 (1.5) 1.00 (Ref) 92.6 (1.1) 1.00 (Ref) 8.1 (1.2) 1.00 (Ref)
25-50 80 93.7 (2.7) 0.44 (0.18 to 1.09) .77 95.0 (2.4) 0.60 (0.22 to 1.67) .33 1.3 (1.3) 0.14 (0.02 to 1.02) .053
. 50 142 82.9 (3.2) 1.35 (0.86 to 2.10) .19 87.2 (2.8) 1.60 (0.94 to 2.73) .084 12.9 (2.8) 1.66 (0.98 to 2.81) .059
Genetics
ETV6-RUNX1 168 95.1 (1.7) 1.00 (Ref) 98.7 (0.9) 1.00 (Ref) 4.9 (1.7) 1.00 (Ref)
DS 40 66.1 (7.8) 8.60 (3.86 to 19.2) , .001 65.2 (8.0) 36.8 (8.31 to 163.3) , .001 6.3 (4.3) 2.17 (0.70 to 6.75) .18
E2A-PBX1 19 100.0* 0.00* 100.0* 0.00* 0.0* 0.00*
HD . 50 182 87.9 (2.5) 2.28 (1.08 to 4.79) .030 93.3 (1.9) 7.84 (1.80 to 34.1) .006 8.9 (2.2) 1.57 (0.72 to 3.45) .26
Other T-lineage 110 80.7 (3.8) 3.93 (1.87 to 8.26) , .001 85.4 (3.4) 14.0 (3.24 to 60.8) , .001 8.5 (2.7) 1.80 (0.76 to 4.25) .18
Other B-lineage 255 86.2 (2.2) 2.62 (1.30 to 5.27) .007 92.8 (1.6) 7.33 (1.72 to 31.2) .007 10.8 (2.0) 1.97 (0.96 to 4.04) .06
DNA index
, 1.16 544 86.6 (1.5) 1.00 (Ref) 91.6 (1.2) 1.00 (Ref) 8.7 (1.2) 1.00 (Ref)
$ 1.16 169 89.9 (2.4) 0.78 (0.47 to 1.29) .33 95.2 (1.7) 0.65 (0.33 to 1.27) .21 7.2 (2.1) 0.80 (0.44 to 1.46) .47
Phenotype
B-lineage 661 88.4 (1.3) 1.00 (Ref) 93.3 (1.0) 1.00 (Ref) 8.1 (1.1) 1.00 (Ref)
T-lineage 116 80.0 (3.7) 1.83 (1.17 to 2.87) .008 84.4 (3.4) 2.25 (1.33 to 3.82) .003 9.0 (2.7) 1.22 (0.65 to 2.03) .52
CNS status†
CNS1 330 89.3 (1.7) 1.00 (Ref) 92.5 (1.5) 1.00 (Ref) 7.4 (1.5) 1.00 (Ref)
CNS2 328 87.8 (1.8) 1.19 (0.77 to 1.83) .44 92.9 (1.4) 1.14 (0.66 to 1.95) .64 8.4 (1.6) 1.19 (0.70 to 2.00) .53
CNS3 8 50.0 (17.7) 6.91 (2.46 to 19.4) , .001 62.5 (17.1) 6.60 (1.99 to 21.9) .002 14.3 (13.2) 2.10 (0.25 to 17.9) .50
TLP+ 80 81.0 (4.4) 1.96 (1.11 to 3.47) .021 90.0 (3.4) 1.68 (0.81 to 3.50) .16 10.4 (3.5) 1.64 (0.80 to 3.38) .18
TLP2 20 75.0 (9.7) 2.47 (0.97 to 6.28) .057 85.0 (8.0) 2.13 (0.64 to 7.06) .22 15.8 (8.4) 2.19 (0.64 to 7.50) .21
Prednisone
response
Good 715 88.1 (1.2) 1.00 (Ref) 93.0 (1.0) 1.00 (Ref) 7.9 (1.0) 1.00 (Ref)
Poor 59 72.9 (5.8) 2.54 (1.52 to 4.27) , .001 78.0 (5.4) 3.28 (1.82 to 5.88) , .001 13.6 (4.5) 1.89 (0.92 to 3.88) .086
MRD‡
SR 198 93.2 (1.8) 1.00 (Ref) 99.0 (0.7) 1.00 (Ref) 6.2 (1.8) 1.00 (Ref)
MR 460 87.7 (1.6) 1.57 (0.92 to 2.70) .099 92.3 (1.3) 4.29 (1.53-12.0) .006 8.5 (1.4) 1.24 (0.69 to 2.23) .18
HR 28 78.4 (7.8) 3.38 (1.40 to 8.14) .007 82.1 (7.2) 12.3 (3.46-43.4) , .001 14.4 (6.7) 2.56 (0.91 to 7.20) .19
Abbreviations: CIR, cumulative incidence of relapse; CSF, cerebrospinal ﬂuid; DS, Down syndrome; EFS, event-free survival; HD, hyperdiploid; HR, high risk; MR,
medium risk; MRD, minimal residual disease; OS, overall survival; Ref, reference; SR, standard risk; TLP, traumatic lumbar puncture.
*No events in these subgroups.
†CNS1: nontraumatic puncture, # 5 WBC/mL CSF without leukemic cells after cytocentrifugation; CNS2: nontraumatic puncture, # 5 WBC/mL CSF with identiﬁable
leukemic cells; CNS3: nontraumatic puncture,. 5 WBC/mL CSF with identiﬁable leukemic cells; TLP+: traumatic lumbar puncture with leukemic cells; TLP2: traumatic
lumbar puncture without leukemic cells.
‡Landmark analysis; only patients with known MRD stratiﬁcation at day 79.
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signiﬁcantly different between boys and girls (EFS 85% v 89% and
OS 91% v 93%, respectively). Children 1 to 4 years of age had
a signiﬁcantly lower 5-year CIR rate of 4.2% (P , .02). The
percentage of adolescents (15 to 18 years old) in the SR, MR, and
HR groups was 3%, 8%, and 15%, respectively. Two of 57 ado-
lescents died before stratiﬁcation (3.5%), six were SR (10.5%), 37
MR (65%), and 12 HR (21%). Seven adolescents (12%) received
alloSCT.
Childrenwith CNS3 or TLP+ had signiﬁcantly lower EFS than
patients with CNS1 (nontraumatic puncture, # 5 WBC/mL CSF
without leukemic cells after cytocentrifugation) status (P , .001
and P = .021, respectively).
T-lineage ALL had a comparable 5-year CIR rate compared
with B-lineage ALL (9.0% and 8.1%, respectively) but lower EFS
and OS because of more toxic deaths (seven of 116 v 13 of 661) and
more second malignancies (three of 116 v two of 661). Six of seven
toxic deaths in T-lineage ALL occurred in the HR group: four after
alloSCT and two after HR chemotherapy.
Relapse rates were low in E2A-PBX1 and ETV6-RUNX1 ALL,
and 5-year OS rates were 100% and 98.7%, respectively. Outcomes
in hyperdiploid and other B-lineage ALL cases were slightly worse
than in these highly favorable genetic subtypes (P = .030 and
P = .007, respectively). The 5-year EFS and OS rates (90.1% and
93.7%, respectively) of trisomies 4, 10, and 17 were not signiﬁ-
cantly better than those of other trisomies (82.6% and 91.3%;
P = .19 and P = .36, respectively). Outcomes of trisomies 17 and 18
were not different than those of other trisomies.
Outcome by Risk Group
Figure 4 and Tables 2 andA5 present outcome by risk group. One
of 194 SR patients died as a result of chickenpox, one died after
a secondarymalignancy, and two after relapse. The 5-year EFS rate was
93.1% (SE 1.9%), the 5-year OS rate 99.0% (SE 0.7%), and the 5-year
CIR rate 6.4% (SE 1.8%). Fifteen of 194 SR patients relapsed; 12 of
these relapses occurred late (32 to 80 months after CR). At the sixth
event, 156 SR patients had a cumulative observation time of 478 years
(reaching the safe upper limit), and therapy reduction for SR patients
was declared safe. Also, at the last update in 2015, the safe upper limit
had been reached (17 events in 194 SR patients with a cumulative
observation time of 1,305 years). The 5-year EFS rate of MRD-based
SR patients (93%, SE 2%, n = 198) was not signiﬁcantly lower than
that of the historical controls (98%, SE 2%, n = 55; P = .08).
For MR patients (n = 490), the 5-year EFS, OS, and CIR rates
were 88.9% (SE 1.5%), 93.2% (SE 1.2%), and 8.4% (SE 1.3%),
respectively. The MRD-based MR group had a higher 5-year EFS
rate (88%, SE 2%, n = 460) than historical controls (76%, SE 6%,
n = 55; P = .056). MR patients with undetectable levels of MRD at
TP2 (n = 301) had a higher 5-year EFS rate of 90.9% (SE 1.7%)
than those with detectable levels ofMRD at TP2 (EFS 84.1%, SE 3.0%;
P = .035).
Intention-to-treat
according to ALL10
(N = 778)
MRD classification
not feasible
(n = 92; 11.8%)
Lack of material
(n = 40; 5.1%)
Relapse, death, or switch to
other protocol because of
toxicity, before TP2
(n = 14; 1.8%)
No PCR-detectable
MRD target
(n = 14; 1.8%)
MRD-PCR targets not
sufficiently sensitive for SR
or HR stratification
(n = 24; 3.1%)
Final risk group: HR
non-MRD HR criteria
(n = 3)
Final risk group: MR
pred-resp inconclusive
(n = 1)
Final risk group: SR
(n = 194)
MRD - SR
(n = 198; 25.5%)
Final risk group: HR
non-MRD HR criteria
(n = 37)
Final risk group: MR
(n = 423)
MRD - MR
(n = 460; 59.1%)
Final risk group: HR
(n = 26)
Final risk group: MR
Down syndrome
(n = 2)
MRD - HR
(n = 28; 3.6%)
MRD classification
feasible
(n = 686; 88.2%)
Fig 2. MRD feasibility andMRD-based classiﬁcation. HR, high risk; MR, medium risk; MRD,minimal residual disease; PCR, polymerase chain reaction; SR, standard risk,
TP2, time point 2.
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For HR patients (n = 81), the 5-year EFS, OS, and CIR rates
were 75.3% (SE 4.8%), 81.5% (SE 4.3%), and 12.3% (SE 3.7%),
respectively. The 5-year EFS rate of MRD-based HR patients (78%,
SE 8%, n = 28) was higher compared with historical controls (16%,
SE 8%, n = 19; P,.001). Outcomes of HR patients, either stratiﬁed
as HR solely by MRD (n = 26) or solely by prednisone response
(n = 44), did not differ.
Fifteen of 81 patients (19%) did not reach SCT, 18 (22%)
received only chemotherapy per protocol, and 48 (59%) received
SCT per protocol. Thus, SCT was performed in 6% of all patients
(48 of 778). Outcomes did not differ between alloSCT and che-
motherapy only, but the study was not designed to make this
comparison. Among 81 HR patients, there were 1 acute un-
differentiated leukemia, 40 B-lineage ALL, and 40 T-lineage
ALL. In B-lineage ALL, 35% received chemotherapy only, 15%
did not reach HR3 per protocol, and 50% underwent trans-
plantation. In T-lineage ALL, these ﬁgures were 10%, 20%, and
70% respectively. Five of 778 patients (0.6%) received cranial
irradiation.
Outcomes of ALL10 Versus ALL9, ALL8, and ALL7
The overall outcome on ALL10 was compared with DCOG
protocols ALL9,24 ALL8,7 and ALL7,25 excluding children older
than 15 years, patients with DS, infants, and Philadelphia
chromosome–positive ALL because of differences in inclusion.
Outcomes improved signiﬁcantly with each consecutive protocol:
the 5-year EFS rates in ALL7, ALL8, ALL9, and ALL10 were 66.1%
(SE 3.3%), 75.4% (SE 2.1%), 83.3% (SE 1.3%), and 88.7%
(SE 1.2%), respectively (P , .001; Table 3).
Toxicity
In SR and MR, infections mainly occurred during IA, IB, and
intensiﬁcation (Table 4). The low intensity of SR intensiﬁcation
phase IV resulted in fewer grade III/IV toxicities, especially in-
fections (4.3%), compared with the MR intensiﬁcation (45.6%;
P , .001). HR patients most often had grade III/IV toxicity;
approximately two-thirds of patients had infections during HR
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Fig 3. Overall event-free survival (EFS), overall survival (OS), and cumu-
lative incidence of relapse (CIR) for ALL10 intention-to-treat patients (N =
778).
Table 2. Overview of Events and 5-Year Outcome Data in ALL10
Variable
Risk Group Based on Intention-to-Treat
SR MR HR Death Before Stratiﬁcation Total No. (%)
Intention-to-treat, No. (%) 194 (100%) 490 (100%) 81 (100%) 13 778 (100.0)
Nonresponder, No. 0 0 2 (1*) 0 2 (0.3)
Death during induction, No. 0 0 0 13† 13 (1.7)
CR achieved after induction, No. (%) 194 (100) 490 (100) 79 (98.8) 0 763 (97.9)
Death during CR, No. 1 12 7 0 20 (2.6)
Relapse, No. 15 44 10 0 69 (8.9)
BM alone 11 (1*) 30 (12*) 5 (4*) 46 (5.9)
BM + CNS 0 5 (3*) 2 (2*) 7 (0.9)
BM + other 1 (1*) 0 1 (1*) 2 (0.3)
CNS alone 2 8 (8*) 1 11 (1.4)
Testis alone 1 1 0 2 (0.3)
Other alone 0 0 1 1 (0.1)
Second malignancy 1 (1*) 2 (2*) 2 (1*) 0 5 (0.6)
Alive during CCR, No. (%) 177 (91.2) 432 (88.2) 60 (74.1) 0 669 (86.0)
Survival, No. 194 490 81 778
Cumulative 5-year EFS, % (SE) 93.1 (1.9) 88.9 (1.5) 75.3 (4.8) 87.0 (1.2)
Cumulative 5-year OS, % (SE) 99.0 (0.7) 93.2 (1.2) 81.5 (4.3) 91.9 (1.0)
5-year CIR all relapses, % (SE) 6.4 (1.8) 8.4 (1.3) 12.3 (3.7) 8.3 (1.0)
5-year CIR isolated CNS relapse, % (SE) 1.0 (0.7) 1.6 (0.6) 1.2 (1.2) 1.4 (0.4)
5-year CIR any CNS relapse, % (SE) 1.0 (0.7) 2.5 (0.7) 3.7 (2.1) 2.3 (0.5)
Abbreviations: BM, bone marrow; CCR, continuous complete remission; CR, complete remission; CIR, cumulative incidence of relapse; EFS, event-free survival; HR,
high risk; MR, medium risk; OS, overall survival; SR, standard risk.
NOTE: Median follow-up time (assessed by reverse Kaplan-Meier method): 80 months (SE 1.6).
*Death.
†Five of these 13 patients did reach CR during induction but died because of induction-related toxicity.
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courses. The incidence of osteonecrosis was 1.6% in patients 1 to
4 years of age, 0.7% in patients 5 to 9 years of age, 8% in patients
10 to 14 years of age, and 27% in patients 15 to 18 years of age.
Patients who were at least 10 years of age had osteonecrosis
more often than younger patients (13.7% v 1.4%, respectively;
P , .001).
DISCUSSION
Our study illustrates that chemotherapy can be substantially re-
duced without jeopardizing outcome in one-quarter of patients
with ALL, ie, those with undetectable PCR-based MRD after the
ﬁrst two chemotherapy courses. SR patients have a 5-year survi-
val rate of 99% and received only nine intrathecal injections,
a mild intensiﬁcation (2 weeks dexamethasone, VCR, and one
PEG-asparaginase dose), followed by oral mercaptopurine/MTX
maintenance. Relapses in SR usually occur late and three-quarters
of these cases can be rescued, because little chemotherapy was
administered at ﬁrst diagnosis.
Others26,27 have also shown that therapy reduction can be
done safely in patients with favorable MRD. These protocols have
different accents. The DCOG ALL10-SR protocol contains sig-
niﬁcantly less dexamethasone (200/200 v 1,050/1,600 mg/m2 for
girls/boys), VCR (9 v 45 to 64 mg/m2), and asparaginase (5 weeks
of coverage v 8 weeks) but more anthracyclines (120 v 75 mg/m2)
and cyclophosphamide (2,000 v 1,000 mg/m2) than the UKALL
2003-SR protocol. The ﬁrst months of SR therapy are more in-
tensive in DCOG ALL10 than in UKALL 2003, whereas the reverse
is true for the latter phases.
The Malaysia-Singapore 2003-SR protocol contains slightly
fewer anthracyclines (60 mg/m2) but more dexamethasone
(560 mg/m2) and VCR (30 mg/m2). Graubner et al28 showed that
reduction of the intensiﬁcation signiﬁcantly reduced the infection
rate. Even before the use of MRD, good outcomes were achieved
with relatively modest therapy, for instance, among National
Cancer Institute SR patients.29 However, all of the ALL subtypes are
heterogeneous, and MRD stratiﬁcation allows patients not ful-
ﬁlling National Cancer Institute standard criteria (such as teen-
agers, T-lineage ALL cases, and cases with high cell counts) into the
SR group.
The percentage of patients in SR was not different than in
the total group for E2A-PBX1 (3% of SR patients v 2% of all
cases), hyperdiploid . 50 (23% v 23%), and other B-lineage
ALL (30% v 33%). The percentage of ETV6-RUNX1 cases was
higher in SR (34%) than in the total group (22%) and lower for
T-lineage ALL (7% v 14%, respectively), reﬂecting the relative
chemosensitivity of ETV6-RUNX1 ALL and chemoresistance of
T-lineage ALL.30-32 In future studies, further reductions in
anthracyclines and cyclophosphamide may be of beneﬁt, es-
pecially in ETV6-RUNX1 ALL.
Outcomes of MR patients improved by using more aspar-
aginase and dexamethasone/VCR pulses. Several studies showed
that intensiﬁcation by asparaginase improved outcome.33 Others
showed that patients with MRD levels $ 1022 after induction
beneﬁtted from postremission intensiﬁcation with asparaginase,
VCR, and MTX.34 The beneﬁt of dexamethasone/VCR pulses
during maintenance remains questionable.35-37
Outcomes of HR patients improved signiﬁcantly with in-
tensive chemotherapy courses and, in most cases, also with
alloSCT. We previously showed the efﬁcacy of ANZCHOG-HR
courses.12 Our HR courses seem to be more effective than the
AIEOP-HR courses (5-year EFS rate 75% v 59% and 5-year OS rate
81% v 69%, respectively).38
Borowitz et al39 showed that intensiﬁcation of therapy in
patients with moderately high MRD after induction delayed the
occurrence of relapses, whereas our data point to lower re-
lapse rates by therapy intensiﬁcation guided by MRD in MR
and HR patients. Relapses in the HR group occurred earlier than in
SR and MR patients (Fig 4C). SR and MR patients showed an
identical pattern of relapses; the difference between these two
groups is the result of toxic deaths and secondary malignancies.
The current study provided additional interesting ﬁndings in
biologic subsets of ALL. First, outcomes were not signiﬁcantly
different between boys and girls, although the trend toward inferior
EFS/OS for boys might have been statistically signiﬁcant with larger
numbers of patients.
Second, the low relapse rate in T-lineage ALL is probably the
result of better stratiﬁcation of T-lineage ALL cases by MRD, as
well as intensive asparaginase treatment in MR and intensive
chemotherapy and alloSCT in HR; 53% and 35% of T-lineage
ALL patients were in the MR and HR groups, respectively.
T-lineage ALL is more drug resistant than B-lineage ALL,32 which
explains the different distributions of T-lineage ALL and B-lin-
eage ALL among MRD risk groups, as has been shown by
others.3,4 The toxic death rate approaches the relapse rate in
T-lineage ALL, illustrating that the limit of treatment intensity
has been reached. Schrappe et al4 used identical stratiﬁcation
criteria and showed that 5-year EFS rates were 91%, 81%, and
50% for SR, MR, and HR T-lineage ALL cases, respectively. Our
Table 3. Outcomes of Consecutive Dutch Childhood Oncology Group Protocols ALL7 (1988 to 1991), ALL8 (1991 to 1997), ALL9 (1997 to 2004), and ALL10
(2004 to 2012)
Outcome ALL7 ALL8 ALL9 ALL10 P
No. 208 420 767 684
5-year EFS % (SE) 66.1 (3.3) 75.4 (2.1) 83.3 (1.3) 88.7 (1.2) ALL10 v ALL8: , .001
ALL10 v ALL9: = .001
5-year OS % (SE) 80.1 (2.8) 85.4 (1.7) 88.3 (1.2) 93.9 (0.9) ALL10 v ALL8: , .001
ALL10 v ALL9: = .002
5-year CIR % (SE) 29.9 (3.2) 22.4 (2.0) 13.1 (1.2) 8.0 (1.1) ALL10 v ALL8: , .001
ALL10 v ALL9: = .008
Abbreviations: CIR, cumulative incidence of relapse; EFS, event-free survival; OS, overall survival.
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study suggests a slightly better outcome for T-lineage ALL, with
5-year EFS rates of 93%, 88%, and 68% for SR, MR, and HR cases,
respectively.
Third, children with E2A-PBX1–positive and ETV6-
RUNX1–positive ALL have excellent 5-year OS rates of 99% to
100%. Hyperdiploid ALL and B-other ALL have 5-year EFS rates of
approximately 87% and OS rates of approximately 93%. Hyper-
diploid ALL cases are particularly sensitive to the antimetabolites
mercaptopurine and MTX;40,41 prolonged asparaginase treatment
in MR patients may have caused myelosuppression, compromising
adequate use of antimetabolites. The B-other ALL group includes
patients with gene expression proﬁles that mimic the unfavorable
BCR-ABL–positive ALL.42 We and others have shown that the
BCR-ABL–like group carries a poor outcome and is characterized
by abnormalities in B-cell differentiation genes such as IKZF1,
CRLF2, and JAK.42-46
Fourth, treatment appeared too toxic for children with DS.
Therapy reduction should, however, be done cautiously, because
DS-ALL patients rarely have genetically favorable subtypes of
ALL47; one-third of patients carry IKZF deletions.48 The percentage
of DS cases was unexpectedly high in our study, with a slightly
negative impact on outcome.
Fifth, older patients were more frequently stratiﬁed as HR,
reﬂecting the fact that cells from older ALL patients are relatively
chemoresistant.32 Also, older patients experience more adverse
effects, especially osteonecrosis.
The major limitation of the current study is its comparison with
historical controls, in which the proportion and composition of risk
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Fig 4. (A) Event-free survival, (B) overall survival, and (C) cumulative incidence of relapse for stratiﬁed ALL10 patients by risk group. Standard risk (SR), N = 194; medium
risk (MR), N = 490; and high risk (HR), N = 81.
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groups may partially differ. Nevertheless, we conclude that chemo-
therapy can be substantially reduced without jeopardizing survival in
one-quarter of children with ALL who have undetectable MRD levels
after induction. Outcomes of patients with intermediate and high
MRD levels were improved by more intensive therapies. Overall,
outcomes improved significantly compared with those of patients on
earlier DCOG protocols.
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Appendix
B
ALL10 SR
6-MP
HD-MTX IV 5,000 mg/m2
(1,000 mg/m2 in children with Down 
syndrome)
Folinic acid (rescue)IV push 15 mg/m2
MTX/ARA-C/DAF ITH acc. to age
DEXA PO 10 mg/m2
VCR IV push 1.5 mg/m2
max 2.0 mg/dose
PEG-ASP IV 2,500 IU/m2
6-MP PO 50 mg/m2
MTX PO 20 mg/m2
PROT M PROT IV SR Maintenance
11 12 13 14 15 16 17 18 19
Weeks
20 21 22 23 24 25 26
Week 104
PO 25 mg/m2
C
ALL10 MR PROT M MR-Intensification MR-Continuation
6-MP
HD-MTX IV 5,000 mg/m2 
(1,000 mg/m2 in children with 
Down syndrome)
Folinic acid (rescue)IV push 
15 mg/m2
MTX/ARA-C/DAF ITH acc. to age
DEXA PO 6 mg/m2
VCR IV push 2 mg/m
2
max 2 mg/dose
DOX IV 30 mg/m2
MTX IV push 30 mg/m2
PEG-ASP IV 2,500 IU/m2
6-MP PO 50 mg/m2
Week 104
14 17 20 23 26 29 32 35
Weeks
38 5311 41 44 47 50 56 59
PO 25 mg/m2
ALL10 INDUCTION PROT IA
A
PROT IB
PRED PO 60 mg/m2
VCR IV push 1.5 mg/m2
max 2.0 mg/dose
DNR
ASP (Escherichia
coli )
IV 1hr 5,000 IU/m2
CPM IV 1hr 1,000 mg/m2
ARA-C IV push 75 mg/m2
6-MP PO 60 mg/m2
MTX ITH acc. to age
MTX/ARA-C/DAF
MRD time point
*Only children with CNS involvement,
    CNS2, or TLP+ at diagnosis.
# Not in children with Down syndrome
ITH acc. to age * *
1
IV 1hr 30 mg/m2 #
## #
2
Weeks
0 1 2 3 4 5 6 7 8 9 10 11
Fig A1. (Continued).
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HR COURSE 1 (HR1)
BMP (to SKION lab)
until neutrophils > 5.0x109/L
LP
NCI toxicity preceding period
days
HD-MTX IV 24hrs 5,000 mg/m2
LEUKOVORIN IV push 15 mg/m2/dose
MTX/ARA-C/DAF ITH acc. to age
6-MP PO 25 mg/m2/day
CPM IV 1hr 1,200 mg/m2/dose
VP-16 IV 2hrs 350 mg/m2/dose
PEG-ASP IV 1hr 1,500 IU/m2/dose
VCR IV push 1.5 mg/m2/dose
max 2.0mg/dose
G-CSF SC 5 g/kg/day
1 8 15 22 29 36 43 50
HR COURSE 2 (HR2)
HD-ARA-C IV 3hrs 1,500mg/m2/dose
HD-MTX IV 24hrs 5,000 mg/m2
LEUKOVORIN IV push 15 mg/m2/dose
MTX/ARA-C/DAF ITH acc. to age
days
BMP (to SKION lab)
LP
NCI toxicity preceding period
until neutrophils > 5.0x109/LG-CSF SC 5 g/kg/day
VCR IV push 1.5 mg/m2/dose
max 2.0mg/dose
1 8 15 22 29 36 43 50
ASP (E.Coli) IV 1hr 10,000 IU/m2/dose
MITOX IV 30min 5.25 mg/m2/dose
HR COURSE 3 (HR3)
days
1 8 15 22 29 36 43 50
HD-ARA-C IV 4hrs 1,500 mg/m2/dose
HD-MTX IV 24hrs 5,000 mg/m2
LEUKOVORIN IV push 15 mg/m2/dose
MTX/ARA-C/DAF ITH acc. to age
BMP (to SKION lab)
LP
NCI toxicity preceding period
G-CSF SC 5 g/kg/day until neutrophils > 5.0x109 /L
FLU IV 30min 22.5 mg/m2/dose
IDA IV 1hr 6 mg/m2/dose
D1
D2
D3
HR COURSE 5 (HR5)
HD-ARA-C IV 3hrs 1,500mg/m2/dose
HD-MTX IV 24hrs 5,000 mg/m2
LEUKOVORIN IV push 15 mg/m2/dose
MTX/ARA-C/DAF ITH acc. to age
days
BMP (to SKION lab)
LP
NCI toxicity preceding period
until neutrophils > 5.0x109/LG-CSF S.C. 5 g/kg/day
VCR IV push 1.5 mg/m2/dose
max 2.0mg/dose
1 8 15 22 29 36 43
50
ASP (E.Coli) IV 1hr 10,000 IU/m2/dose
MITOX IV 30min 5.25 mg/m2/dose
HR COURSE 6 (HR6)
days
1 8 15 22 29 36 43 50
HD-ARA-C IV 4hrs 1,500 mg/m2/dose
HD-MTX IV 24hrs 5,000 mg/m2
LEUKOVORIN IV push 15 mg/m2/dose
MTX/ARA-C/DAF ITH acc. to age
BMP (to SKION lab)
LP
NCI toxicity preceding period
G-CSF SC 5 g/kg/day until neutrophils > 5.0x109 /L
FLU IV 30min 22.5 mg/m2/dose
HR COURSE 4 (HR4)
LEUKOVORIN
MTX/ARA-C/DAF
CPM IV 1hr 900 mg/m2/dose
VP-16
ASP (E.Coli)
VCR
G-CSF
BMP (to SKION lab)
LP
NCI toxicity preceding period
until neutrophils > 5.0x109 /L
days
1 8 15 22 29 36 43 50
HD-MTX IV 24hrs 5,000 mg/m2
IV push 15 mg/m2/dose
ITH acc. to age
IV 2hrs 275 mg/m2/dose
IV 1hr 10,000 IU/m2/dose
IV push 1.5 mg/m2/dose
max 2.0 mg/dose
SC 5 g/kg/day
D4
D5
D6
HR-MAINTENANCE
MTX
BMP (to SKION lab)
LP
NCI toxicity preceding period
373174 10 13 16 19 22 25 28 341
weeks
PO 20 mg/m2/week
6-MP PO 50 mg/m2/day
PROTOCOL II (A and B)
VCR
DOX
ASP (E.Coli)
CPM
6-TG
ARA-C
MTX/ARA-C/DAF
**
*Only children with CNS involvement, CNS2 or
TLP+ at diagnosis.
**
**12 Gy cranial irradiation in 8 fractions only for
children > 3 years who will not get stem cell
transplantation
BMP (to SKION lab)
LP
NCI toxicity preceding period
days
1 8 15 22 29 36 43 50 57
DEXA PO 10 mg/m2/day
IV push 1.5 mg/m2/dose
max 2.0 mg/dose
IV 1hr 30 mg/m2/dose
IV 1hr 10,000 IU/m2/dose
IV 1hr 1,000 mg/m2/dose
PO 60 mg/m2/day
IV/SC push 75 mg/m2/dose
ITH acc. to age
D7
D8
Fig A1. (Continued).
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Criteria for SCT
E
SCT grorup
MSD MD MMD
PGR + t(9;22) + + –
PGR + t(4;11) # + – –
PPR + T-ALL* + +* –
PPR + pro-B-ALL + + –
PPR + M3 BM on day 15 + + –
PPR + initial WBC > 100×109/L + + –
PPR + t(9;22) + + +
PPR + t(4;11) # + + –
No CR on day 33 + + +
MRD at time point 2 (~d 79)3 10–3 + + +
Abbreviations: MSD: Matched Sibling Donor; MD: Matched Donor (related or unrelated, 10/10 or 9/10 match); MMD:
MisMatched Donor (related or unrelated, less than 9/10 match); PGR: prednisone good responder on day 8; PPR: prednisone
poor responder on day 8; MRD: minimal residual disease.
* If MRD at time point 2 (~d 79) negative, MD SCT is not indicated
# Special conditioning regimens for t(4;11)
If MRD inconclusive: contact SCT centre
Fig A1. Overview of ALL10 treatment schedule. (A) Induction. (B) SR. (C)MR. (D) HR. After three HR courses, HR patientswith one of the following characteristics are eligible for
SCT if a donor is available: a) poor prednisone response in combinationwith T-ALL or Pro-B-ALL orM3BMat day 15 orWBC. 1003 109/L; b) no complete remission on day 33; c)
time point 2 MRD $ 1023; d) presence of t(4;11) or MLL-AF4; or e) presence of t(9;22) or BCR-ABL with no informed consent for EsPhALL protocol. HR patients who are not
transplanted and who are older than 3 years will receive 12 Gy in eight fractions prophylactic cranial radiotherapy after protocol II. Patients for whom an SCT is planned will receive
prophylactic cranial irradiation in conjunction with the conditioning regimen, which includes TBI for children who are at least 2 years old. (E) SCT. *If MRD at time point 2
(approximately day 79) is negative, MD SCT is not indicated. #Special conditioning regimens for t(4;11). If MRD is inconclusive, contact the SCT center. Abbreviations: 6-MP,
mercaptopurine; 6-TG, thioguanine; acc., according; ARA-C, cytarabine; ASP, asparaginase; BM, bone marrow; CNS2, nontraumatic puncture, # 5 WBC/mL CSF with identiﬁable
leukemic cells; CPM, cyclophosphamide; CR, complete remission; DAF, prednisolone; DEXA, dexamethasone; DNR, daunorubicin; DOX, doxorubicin; FLU, ﬂudarabine; G-CSF,
granulocyte colony-stimulating factor; HD-ARA-C, high-dose cytarabine; HD-MTX, high-dosemethotrexate; hr, hour; HR, high risk; IDA, idarubicin; ITH, intrathecally; IV, intravenously;
maint.,maintenance;max,maximum;MD,matched donor (related or unrelated, 10/10 or 9/10match);MITOX,mitoxantrone;MMD,mismatched donor (related or unrelated,, 9/10
match); MR, medium risk; MRD, minimal residual disease; MSD, matched sibling donor; MTX, methotrexate; PGR, prednisone good responder on day 8; PO, orally administered;
PPR, prednisone poor responder on day 8; PRED, prednisone; PROT, protocol; SC, subcutaneously administered; SCT, stem cell transplantation; SR, standard risk; TBI, total-body
irradiation; TLP+, traumatic lumbar puncture with leukemic cells; VCR, vincristine; VP-16, etoposide.
Table A1. Comparison of Cumulative Doses of Chemotherapy in Dutch Childhood Oncology Group ALL10With a Contemporary Protocol (BFM-2000) Using the Same
Stratifying Criteria
Protocol Phase Drug DCOG ALL10 BFM-2000 Additional Information
IA IA IA Identical
IB IB IB Identical
IV IIA/IIB
IIA/IV Vincristine (mg/m2) 3 6
IIA/IV Doxorubicin (mg/m2) 0 120
IA/IIA/IV Dexamethasone (mg/m2) 140 140 Plus tapering in both protocols
IA/IIA/IV Native Escherichia coli asparaginase (U/m2) 40.000 80.000
PEG-asparaginase (U/m2) 2.500 0
IB/IIB/IV Cyclophosphamide (mg/m2) 2.000 3.000
IB/IIB/IV Cytosine arabinoside (g/m2) 1.200 1.800
IB/IV Mercaptopurine (mg/m2) 1.680 1.680
IIB/IV Thioguanine (mg/m2) 0 840
M M M Identical
Maintenance Maintenance Maintenance Identical
Abbreviation: DCOG, Dutch Childhood Oncology Group.
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Table A2. Stopping Rules for ALL10 Standard Risk
No. of Events Lower Limit Upper Limit
2 — 307
4 29 388
6 110 469
8 191 550
10 272 631
12 353 712
14 434 793
16 515 875
18 596 956
20 677 1,037
22 758 1,118
24 840 1,199
26 921 1,280
28 1,002 1,361
30 1,083 1,442
32 1,164 1,523
34 1,245 1,604
36 1,326 1,685
38 1,407 1,767
40 1,488 1,848
42 1,569 1,929
44 1,650 2,010
46 1,732 2,091
48 1,813 2,172
50 1,894 2,253
NOTE: For each speciﬁc number of events, the corresponding upper and lower
limits for the cumulative observation time T has been precalculated. If, for a given
number of events, the corresponding T is below the lower limit, the protocol is
declared unsafe and therefore must be stopped. On the other hand, if for the
same number of events T is above the upper limit, the protocol is declared to be
safe. The minimum number of events required to declare the protocol unsafe is
four and two to declare the protocol safe.
Table A3. Outcome of Down Syndrome Versus Non-Down Syndrome Pa-
tients: Overall and by Risk Group
Outcome DS ALL, % (SE) Non-DS ALL, % (SE) Total, % (SE)
Patients, No. 40 738 778
5-year EFS 66.1 (7.8) 88.1 (1.2) 87.0 (1.2)
5-year OS 65.2 (8.0) 93.3 (0.9) 91.9 (1.0)
5-year EFS SR 100 92.8 (1.9) 93.1 (1.9)
5-year OS SR 100 98.9 (0.8) 99.0 (0.7)
5-year EFS MR 74.6 (9.2) 89.6 (1.5) 88.9 (1.5)
5-year OS MR 73.3 (9.6) 94.2 (1.1) 93.2 (1.2)
Abbreviations: DS, Down syndrome; EFS, event-free survival; MR,medium risk;
OS, overall survival; SR, standard risk.
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Table A4. Multivariate Survival Analysis (Event-Free Survival, Overall Survival, and Cumulative Incidence of Relapse) by Patient Characteristics
Variable No. of Patients
EFS* OS* CIR†
Estimated Hazard Ratio (CI) P Estimated Hazard Ratio (CI) P Estimated Hazard Ratio (CI) P
Sex
Male 377 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Female 327 0.82 (0.54 to 1.25) .36 0.87 (0.50 to 1.49) .61 0.80 (0.48 to 1.36) .42
Age, years
1-4 328 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
5-9 217 1.65 (0.99 to 2.73) .053 1.45 (0.76 to 2.77) .26 3.02 (1.57 to 5.83) , .005
10-14 112 2.04 (1.14 to 3.66) .016 1.48 (0.68 to 3.24) .33 3.70 (1.78 to 7.69) , .005
15-18 47 1.91 (0.88 to 4.13) .10 1.88 (0.76 to 4.65) .17 2.44 (0.84 to 7.07) .10
WBC count
, 25 487 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
25-50 77 0.23 (0.070 to 0.73) .013 0.40 (0.12 to 1.33) .13 0.00‡
. 50 140 1.09 (0.60 to 2.00) .77 1.18 (0.55 to 2.56) .67 2.15 (1.15 to 4.03) .02
Genetics
ETV6-RUNX1 159 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
DS 36 10.31 (4.60 to 23.1) , .001 43.7 (9.80 to 194.9) , .001 2.84 (0.87 to 9.25) .08
E2A-PBX1 19 0.00‡ 0.00‡ 0.00‡
HD . 50 167 2.72 (1.15 to 6.40) .022 10.6 (2.24 to 49.9) .003 2.29 (0.86 to 6.11) .10
Other T-lineage 102 1.13 (0.22 to 5.98) .88 3.15 (0.38 to 26.4) .29 0.66 (0.06 to 7.63) .74
Other B-lineage 221 1.92 (0.92 to 4.01) .084 4.34 (0.97 to 19.5) .056 1.61 (0.75 to 3.43) .22
DNA index
, 1.16 536 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
$ 1.16 168 0.68 (0.36 to 1.30) .25 0.49 (0.21 to 1.12) .091 0.61 (0.26 to 1.42) .25
Phenotype
B-lineage 596 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
T-lineage 108 1.93 (0.41 to 9.03) .40 2.16 (0.42 to 11.2) .36 1.22 (0.12 to 12.33) .87
Prednisone response
Good 648 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Poor 56 1.68 (0.85 to 3.29) .13 2.30 (1.04 to 5.08) .040 0.80 (0.33 to 1.90) .61
MRD§
SR 179 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
MR 422 1.29 (0.72 to 2.30) .39 2.57 (0.88 to 7.44) .083 1.14 (0.61 to 2.13) .68
HR 26 2.07 (0.78 to 5.49) .14 4.87 (1.24 to 19.2) .024 2.15 (0.71 to 6.54) .18
Abbreviations: CIR, cumulative incidence of relapse; DS, Down syndrome; EFS, event-free survival; HD, hyperdiploid; HR, high risk; MR, medium risk; MRD, minimal
residual disease; OS, overall survival; Ref, reference; SR, standard risk.
*Multivariate Cox Regression.
†Multivariate Fine and Gray Model.
‡No events in these subgroups.
§Landmark analysis; only patients with known MRD stratiﬁcation at day 79.
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Table A5. Overview of Patient Characteristics by Final Risk Group and Outcome
Variable No. of Patients
Early Deaths,
No. (%)
SR, Final Risk
Group, No. (%)
SR, 5-Year
EFS, % (SE)
MR, Final Risk
Group, No. (%)
MR, 5-Year
EFS, % (SE)
HR, Final Risk
Group, No. (%)
HR, 5-Year EFS,
% (SE)
Sex
Male 420 6 (46) 95 (49) 89.2 (3.2) 265 (54) 87.7 (2.1) 54 (67) 75.9 (5.8)
Female 358 7 (54) 99 (51) 97.0 (1.7) 225 (46) 90.3 (2.0) 27 (33) 74.1 (8.4)
Age, years
1-4 361 5 (39) 99 (51) 96.0 (2.0) 236 (48) 92.4 (1.8) 21 (26) 81.0 (8.6)
5-9 230 2 (15) 67 (35) 90.7 (3.6) 130 (27) 87.9 (2.9) 31 (38) 74.2 (7.9)
10-14 130 4 (31) 22 (11) 86.4 (7.3) 87 (18) 83.0 (4.2) 17 (21) 76.5 (10.3)
15-18 57 2 (15) 6 (3) 100.0 37 (8) 83.8 (6.1) 12 (15) 66.7 (13.6)
WBC count
, 25 554 10 (77) 159 (82) 93.5 (2.0) 356 (73) 87.6 (1.8) 29 (36) 75.9 (7.9)
25-50 80 3 (23) 14 (7) 92.9 (6.9) 55 (11) 98.2 (1.8) 8 (10) 100.0
. 50 142 0 (0) 21 (11) 90.5 (6.4) 78 (16) 88.0 (3.8) 43 (54) 69.8 (7.0)
Genetics
ETV6-RUNX1 168 0 (0) 65 (34) 92.2 (3.3) 101 (21) 96.8 (1.8) 2 (3) 100.0
DS 40 7 (54) 7 (4) 100.0 26 (5) 74.6 (9.2) 0 (0) —
E2A-PBX1 19 0 (0) 6 (3) 100.0 12 (2) 100.0 1 (1) 100.0
HD . 50 182 2 (15) 45 (23) 96.9 (3.1) 123 (25) 89.0 (2.9) 12 (15) 58.3 (14.2)
Other T-lineage 110 2 (15) 13 (7) 92.3 (7.4) 59 (12) 87.8 (4.3) 36 (47) 69.4 (7.7)
Other B-lineage 255 2 (15) 58 (30) 89.6 (4.0) 169 (35) 85.7 (2.8) 26 (34) 88.5 (6.3)
DNA index
, 1.16 544 10 (91) 128 (72) 92.2 (2.4) 335 (75) 89.3 (1.7) 71 (91) 76.1 (5.1)
$ 1.16 169 1 (9) 49 (28) 95.2 (3.4) 112 (25) 89.6 (3.0) 7 (9) 71.4 (17.1)
Phenotype
B-lineage 661 11 (85) 180 (93) 93.1 (1.9) 430 (88) 89.0 (1.6) 40 (50) 85.0 (5.6)
T-lineage 116 2 (15) 14 (7) 92.9 (6.9) 60 (12) 88.0 (4.3) 40 (50) 67.5 (7.4)
CNS status*
CNS1 330 4 (31) 85 (45) 92.6 (2.9) 216 (45) 90.7 (2.0) 25 (31) 80.0 (8.0)
CNS2 328 6 (46) 81 (43) 95.0 (2.4) 198 (41) 89.9 (2.2) 43 (54) 76.7 (6.4)
CNS3 8 1 (8) 0 (0) — 6 (1) 66.7 (19.2) 1 (1) 100.0
TLP+ 80 1 (8) 18 (9) 88.5 (7.6) 51 (11) 83.9 (5.2) 10 (13) 60.0 (15.5)
TLP2 20 1 (8) 6 (3) 83.3 (15.2) 12 (3) 75.0 (12.5) 1 (1) 0
Abbreviations: CSF, cerebrospinal ﬂuid; DS, Down syndrome; EFS, event-free survival; HD, hyperdiploid; HR, high risk; MR, medium risk; SR, standard risk; TLP,
traumatic lumbar puncture.
*CNS1: nontraumatic puncture, # 5 WBC/mL CSF without leukemic cells after cytocentrifugation; CNS2: nontraumatic puncture, # 5 WBC/mL CSF with identiﬁable
leukemic cells; CNS3: nontraumatic puncture,. 5 WBC/mL CSF with identiﬁable leukemic cells; TLP+: traumatic lumbar puncture with leukemic cells; TLP2: traumatic
lumbar puncture without leukemic cells.
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